^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    farudodstat (ASLAN003)

    i
    Other names: ASLAN003, LAS-186323, ASLAN 003
    Associations

    News

    Trials
    Company:
    ASLAN Pharma, Almirall
    Drug class:
    DHODH inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    FAST-AA: Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants (clinicaltrials.gov)
    P2, N=60, Recruiting, ASLAN Pharmaceuticals | Phase classification: P2a --> P2 | Trial completion date: Apr 2024 --> Oct 2024 | Trial primary completion date: Feb 2024 --> Sep 2024
    Phase classification • Trial completion date • Trial primary completion date
    |
    farudodstat (ASLAN003)
    4years
    ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia. (PubMed, Haematologica)
    Our results, therefore, suggest that ASLAN003 is an agent targeting dihydroorotate dehydrogenase with potential in the treatment of acute myeloid leukemia. ASLAN003 is currently being evaluated in phase 2a clinical trial in acute myeloid leukemia patients.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation
    |
    farudodstat (ASLAN003)